Clovis Oncology Inc. (NASDAQ:CLVS) was a big mover after reporting impressive fourth-quarter and full-year results at the back of a challenging macro environment owing to COVID-19 shocks. The biopharmaceutical company was up by more than 3% as investors reacted to revenue growth at the back of key pipeline developments.
Sales Growth Boost
The Colorado-based company reported global net product revenue of $43.3 billion for Rubraka, representing a 10% year over year increase. Rubraka's net product revenues for the whole year totaled $164.5 million, representing a 15% increase from 2019 levels. A good chunk of the sales came from the U.S market, with U.S sales totaling $36.4 million in the fourth quarter and $146.3 million for the full year.
Owing to the COVID-19 disruptions, Clovis Oncology embarked on a cost-cutting drive. Similarly, Research and development expenses shrunk 22% in the fourth quarter to $56.7 million and 9% for the whole year to $257.7 million.
Cost Cutting Spree
The lower-than-expected R&D expenditure came as the company reduced its spending on its clinical trials for Rubraka. The company also expects its full-year R&D expenditure to be much lower in 2020 compared to 2020 levels.
The biopharmaceutical company also cut its spending on Selling, general and administrative, which were down 10% in the fourth quarter to $20.8 million and 10% down for the full year to 182.8 million.
Fourth-quarter net loss shrunk slightly to $99 million or $1.02 a share compared to a net loss of $99.5 million or $1.81 a share reported the prior year. Full-year net loss, on the other hand, shrunk to $369.2 million or $4.38 a share compared to a net loss of $400.4 million or $7.43 a share reported in 2019.
The impressive fourth-quarter and full-year results might as well be the catalyst to steer the stock high after a recent correction from one-year highs. Clovis Oncology has shed more than 50% of the gains accrued since the start of the year.